Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
AIP insider Paul Lawrence Alpern has filed to sell 18,500 shares of common stock on 08/03/2026, to be issued upon the cash exercise of stock options and listed on NASDAQ. The notice also lists recent sales under a Rule 10b5-1 trading plan, including 6,003 shares for $215,587.30 on 07/06/2026, 3,648 shares for $141,461.78 on 07/02/2026, 6,500 shares for $295,513.85 on 07/01/2026, and 12,502 shares for $450,285.78 on 06/01/2026.
Atiq Raza & N. Saraiya 2012 Revocable Trust, as reported owner of AIP common stock, filed to sell 70,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $2,091,600, expected to be sold on or after August 3, 2026 on NASDAQ. The shares were acquired on December 28, 2020 via previously exercised stock options for cash. Over the past three months, the trust reported additional 10b5-1 sales of AIP common stock, including 70,000 shares for $3,176,978 on July 1, 2026, 20,839 shares for $779,174.38 on June 3, 2026, and 70,000 shares for $2,521,106 on June 1, 2026.
BlackRock, Inc. reports a passive ownership stake in Arteris, Inc. common stock on Schedule 13G. BlackRock and certain of its business units are deemed to beneficially own 2,884,824 shares of Arteris common stock, representing 6.2% of the class as of June 30, 2026.
BlackRock has sole voting power over 2,828,242 shares and sole dispositive power over 2,884,824 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends and sale proceeds, but no single client holds more than five percent of Arteris’s total outstanding common shares.
Arteris, Inc. director, President and CEO K. Charles Janac reported open-market sales of common stock mainly through indirect holdings. On July 6, 2026, entities associated with him sold an aggregate of 136,655 shares of Arteris common stock in several transactions.
The reported sales, including those by Bayview Legacy, LLC and direct holdings, occurred at weighted average prices between roughly $35 and $37 per share. According to the disclosure, these trades were executed under a Rule 10b5-1 trading plan adopted on December 12, 2025, and Janac continues to hold substantial direct and indirect positions, including shares in the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported open-market sales of a total of 125,976 shares of common stock on July 6, 2026. The sales were executed in three tranches at weighted average prices of $35.065, $36.2365, and $37.0705 per share.
The trades were made pursuant to a Rule 10b5-1 trading plan adopted by K. Charles Janac, the manager of Bayview Legacy, LLC, on December 12, 2025. Janac is deemed to have voting and dispositive power over the shares held by Bayview Legacy, and he has separately filed a Form 4 reflecting the same transactions.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported selling 6,003 shares of common stock in open-market transactions on July 6, 2026. The sales were executed at weighted average prices in ranges between $34.65 and $37.57 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 70,733 shares of Arteris common stock.
Kunkel Joachim reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Joachim Kunkel reported receiving a grant of 365 shares of common stock as fully vested restricted stock. These shares represent director retainer fees that he chose to take in stock instead of cash, at no cash cost per share. The grant was calculated using an average Arteris trading price of $39.28 over a defined period, and Kunkel elected to defer the actual receipt of the shares, leaving his reported direct holdings at 74,695 shares after the award.
Munce Claudia F. reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Claudia F. Munce received an award of 350 shares of common stock as fully vested restricted stock. According to the disclosure, this represents retainer fees she elected to take in stock instead of cash, valued using an average trading price of $39.28.
The grant was made on July 5, 2026 and brings her directly held position to 106,764 common shares. The filing also notes that she elected to defer the actual receipt of the shares, indicating this is structured as deferred equity compensation rather than an open-market purchase.
Arteris, Inc. director, President and CEO K. Charles Janac reported multiple sales of Arteris common stock on July 2, 2026. The Form 4 shows net sales of 203,588 shares at various weighted average prices between $34.20 and $43.51 per share.
According to the footnotes, a portion of the shares was sold to satisfy Mr. Janac’s tax liability from the release of restricted stock units under the company’s equity incentive plans, using mandatory “sell to cover” transactions rather than discretionary trades. Additional sales were made by Bayview Legacy, LLC under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025.
After these transactions, Mr. Janac continues to hold Arteris shares both directly and indirectly, including 56,252 shares held by the Charles and Lydia Janac Trust, 193,508 shares held directly, and 8,736,733 shares beneficially owned through Bayview Legacy, LLC.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of 192,686 shares of Arteris common stock. The trades occurred on July 2, 2026 across eight transactions at weighted average prices between $34.77 and $43.24 per share. The filing notes that these sales were made pursuant to a Rule 10b5-1 trading plan adopted by Bayview’s manager, K. Charles Janac, on December 12, 2025, indicating the transactions were pre-scheduled rather than opportunistic.